Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

NCT01282762 · clinicaltrials.gov ↗

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

BIOLOGICAL: HEPLISAV
BIOLOGICAL: Engerix-B

Sponsor

Dynavax Technologies Corporation